Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.85 USD
Change Today +0.10 / 3.64%
Volume 588.2K
OHRP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ohr pharmaceutical inc (OHRP) Snapshot

Open
$2.70
Previous Close
$2.75
Day High
$2.88
Day Low
$2.68
52 Week High
03/5/15 - $12.31
52 Week Low
07/8/15 - $2.02
Market Cap
86.4M
Average Volume 10 Days
1.2M
EPS TTM
$-0.60
Shares Outstanding
30.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OHR PHARMACEUTICAL INC (OHRP)

ohr pharmaceutical inc (OHRP) Related Bloomberg News

View More Bloomberg News

ohr pharmaceutical inc (OHRP) Related Businessweek News

No Related Businessweek News Found

ohr pharmaceutical inc (OHRP) Details

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes. The company is evaluating OHR-102 eye drops in various Phase II studies for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. The company is headquartered in New York, New York.

13 Employees
Last Reported Date: 12/22/14

ohr pharmaceutical inc (OHRP) Top Compensated Officers

Founder, President, Chief Technology Officer ...
Total Annual Compensation: $219.0K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $177.7K
Compensation as of Fiscal Year 2014.

ohr pharmaceutical inc (OHRP) Key Developments

Ohr Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

Ohr Pharmaceutical, Inc. reported earnings results for the third quarter and nine months ended June 30, 2015. The company recognized a net loss of approximately 3.3 million compared to a net loss of approximately 2.0 million for the same period in 2014. The company recognized a net loss of approximately 11.3 million, compared to a net loss of approximately 6.0 million for the same period in 2014.

Ohr Pharmaceutical, Inc. Announces Executive Changes, Effective August 07, 2015

Ohr Pharmaceutical, Inc. announced that Jason S. Slakter, MD, has been appointed Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the company's sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the company's board of directors. Dr. Slakter joined Ohr as Chief Medical Officer in May 2014 and was appointed board member in January 2015. He was previously Chief Executive Officer and co-founder of SKS Ocular LLC. He is also the Founder and Director of the Digital Angiography Reading Center (DARC) in New York. Dr. Slakter served as Chief Medical Officer for Potentia Pharmaceuticals from its inception through its acquisition by Alcon Laboratories, Inc. (Novartis). Dr. Slakter is a member of The American Ophthalmological Society, The Macula Society, The Retina Society, and The American Society of Retina Specialists, and was the founder and first Editor-in-Chief of Retinal Physician journal.

Ohr Pharmaceutical, Inc. to Report Q3, 2015 Results on Aug 06, 2015

Ohr Pharmaceutical, Inc. announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OHRP:US $2.85 USD +0.10

OHRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OHRP.
View Industry Companies
 

Industry Analysis

OHRP

Industry Average

Valuation OHRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OHR PHARMACEUTICAL INC, please visit www.ohrpharmaceutical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.